Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.8.3583

SENP2 Regulates Hepatocellular Carcinoma Cell Growth by Modulating the Stability of β-catenin  

Shen, Huo-Jian (Department of General Surgery, Renji hospital of Shanghai Jiao Tong University School of Medicine)
Zhu, Hong-Yi (Department of General Surgery, Renji hospital of Shanghai Jiao Tong University School of Medicine)
Yang, Chao (Department of General Surgery, Renji hospital of Shanghai Jiao Tong University School of Medicine)
Ji, Fu (Department of General Surgery, Renji hospital of Shanghai Jiao Tong University School of Medicine)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.8, 2012 , pp. 3583-3587 More about this Journal
Abstract
SUMOylation has emerged as an important post-translational modification that modulates the localization, stability and activity of a broad spectrum of proteins. A dynamic process, it can be reversed by a family of SUMO-specific proteases (SENPs). However, the biological roles of SENPs in mammalian development and pathogenesis remain largely elusive. Here, we demonstrated that SENP2 plays a critical role in the control of hepatocellular carcinoma cell growth. SENP2 was found to be down-regulated in hepatocellular carcinoma (HCC) tissues and over-expression suppressed the growth and colony formation of HCC cells. In contrast, silencing of SENP2 by siRNAs promoted cancer cell growth. We further found that stability of ${\beta}$-catenin was markedly decreased when SENP2 was over-expressed. Interestingly, the decrease was dependent on the de-SUMOylation activity of SENP2, because over-expression of a SENP2 catalytic mutant form had no obviously effects on ${\beta}$-catenin. Our results suggest that SENP2 might play a role in hepatocellular carcinoma cell growth control by modulating the stability of ${\beta}$-catenin.
Keywords
SENP2; ${\beta}$-catenin; hepatocellular carcinoma; HepG2 cells;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Chiu SY, Asai N, Costantini F, et al (2008). SUMO-specific protease 2 is essential for modulating p53-Mdm2 in development of trophoblast stem cell niches and lineages. PLoS Biol, 6, e310.   DOI   ScienceOn
2 David R (2010). Sumoylation: Targeting SUMO. Nat Rev Mol Cell Biol, 11, 387.
3 Di Bacco A, Gill G (2006). SUMO-specific proteases and the cell cycle. An essential role for SENP5 in cell proliferation. Cell Cycle, 5, 2310-3.   DOI
4 Geiss-Friedlander R, Melchior F (2007). Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol, 8, 947-56.   DOI
5 Haindl M, Harasim T, Eick T, et al (2008). The nucleolar SUMOspecific protease SENP3 reverses SUMO modification of nucleophosmin and is required for rRNA processing. EMBO Rep, 9, 273-9.   DOI
6 Hang J, Dasso M (2002). Association of the human SUMO-1 protease SENP2 with the nuclear pore. J Biol Chem, 277, 19961-6.   DOI
7 Huang H, He X (2008). Wnt/beta-catenin signaling: new (and old) players and new insights. Curr Opin Cell Biol, 20, 119-25.   DOI   ScienceOn
8 Itahana Y, Yeh ET, Zhang Y (2006). Nucleocytoplasmic shuttling modulates activity and ubiquitination-dependent turnover of SUMO-specific protease 2. Mol Cell Biol, 26, 4675-89.   DOI
9 Kang X, Qi Y, Zuo Y, et al (2010). SUMO-specific protease 2 is essential for suppression of polycomb group proteinmediated gene silencing during embryonic development. Mol Cell, 38, 191-201.   DOI
10 Lam AP, Gottardi CJ (2011). Beta-catenin signaling: a novel mediator of fibrosis and potential therapeutic target. Curr Opin Rheumatol, 23, 562-7.   DOI
11 Li SJ, Hochstrasser M (1999). A new protease required for cellcycle progression in yeast. Nature, 398, 246-51.   DOI
12 MacDonald BT, Tamai K, He X (2009). Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell, 17, 9-26.   DOI
13 Vertegaal AC (2010). SUMO chains: polymeric signals. Biochem Soc Trans, 38, 46-49.   DOI
14 Wang Y, Dasso M (2009). SUMOylation and deSUMOylation at a glance. J Cell Sci, 122, 4249-52.   DOI
15 White BD, Chien AJ, Dawson DW (2012). Dysregulation of Wnt/beta-catenin signaling in gastrointestinal cancers. Gastroenterology, 142, 219-32.   DOI
16 Woo CH, Abe J (2010). SUMO--a post-translational modification with therapeutic potential? Curr Opin Pharmacol, 10, 146-55.   DOI
17 Zhang XF, Tan X, Zeng G, et al (2010). Conditional beta-catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor receptor alpha/phosphoinositide 3-kinase signaling. Hepatology, 52, 954-65.
18 Yeh JJ, Hsu NY, Hsu WH, et al (2005). Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer. Lung, 183, 177-83.   DOI   ScienceOn
19 Bawa-Khalfe T, Yeh ET (2010). SUMO Losing Balance: SUMO Proteases Disrupt SUMO Homeostasis to Facilitate Cancer Development and Progression. Genes Cancer, 1, 748-52.   DOI
20 Cavard, C, S Colnot, V Audard, et al (2008). Wnt/beta-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology. Future Oncol, 4, 647-60.   DOI
21 Cheng J, Bawa T, Lee P, et al (2006). Role of desumoylation in the development of prostate cancer. Neoplasia, 8, 667-76.   DOI
22 Cheng J, Kang X, Zhang S, et al (2007). SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell, 131, 584-95.   DOI